Sifi Mexico – Juan José Davidovich, General Manager
Juan José Davidovich, general manager of the Italian ophthalmology leader Sifi, speaks about the importance of Mexico as a base to enter Latin America and sets the goal of prospering…
SIFI has made the history of ophthalmology in Italy and has worked in the eye care sector since 1935. Italian market leader for over 15 years, it develops, produces and markets innovative pharmaceutical treatments, tools for diagnosis and surgical devices for prevention and care of the most common ocular pathologies. Since its foundation in 1935, SIFI has displayed a constant commitment to working alongside ophthalmologists. Being close to practitioners, sharing their passion for EyeCare and contributing to the improvement of disease management in ophthalmology is indeed SIFI’s principal concern. The development plans for Latin America has included the constitution in 2007 of a fully owned subsidiary, Laboratorios SIFI de México, which aims to become one of the main players in the local ophthalmic pharmaceutical sector.
Contact details
SIFI de México
Dante 36, Piso 11, Oficina 1101
Col. Anzures, Del. Miguel Hidalgo
CP 11590 México DF
MÉXICO
Tel: +52 (55) 5263 2450
Website: www.sifi.it
Juan José Davidovich, general manager of the Italian ophthalmology leader Sifi, speaks about the importance of Mexico as a base to enter Latin America and sets the goal of prospering…
The Mexican Association of Pharmaceutical Research Industries (AMIIF) represents the innovative pharmaceutical industry in Mexico, advocating for innovation and promoting dialogue with local authorities. AMIIF’s Executive Director, Cristobal Thompson, discusses…
Latin America (LatAm) Area Lead for Astellas Sandra Ramirez outlines the Japanese company’s presence in the region, its efforts to partner with local stakeholders to improve patient access, and the…
Mexico’s pharma market, the second largest in Latin America and among the top 15 globally, is set to top USD 13 billion in sales by 2028. Despite the encouraging numbers,…
The director of Mexican pharmaceutical industry association CANIFARMA, Rafael Gual Cosío, speaks out about the current contradictions plaguing Mexico’s pharma sector. Gual Cosío highlights the fact that market growth and…
The latest from Latin American pharma, including Moderna’s push to build a regional presence and partnership network; Pfizer’s health equity challenges in the region; and Brazil’s local manufacturing of AstraZeneca’s…
The latest from Mexican pharma, including government talks with Indian authorities to provide low-cost medicines, a new distribution pilot program led by the military, the authorization of two Lilly monoclonal…
Writing in the November issue of DIA Global Forum, Lawrence Liberti, Mario Alanis, Pravin Chopra, and Silvia Bendiner examine how the COVID-19 pandemic facilitated greater inter-stakeholder collaboration across the healthcare…
During a year where the Mexican economy shrank 8.5 percent, Novartis Mexico experienced a modest one percent growth which Country President Fernando Cruz, qualified as “reasonably good” considering the impacts…
The latest news from Mexican pharma, including Bayer’s big bet on oncology and Novartis’ aggressive expansion strategy as well as updates on the country’s vaccination drive, including the upcoming rollout…
While Mexico struggles with its COVID-19 vaccination campaign, residents of the country’s northern states have begun flying to the United States in search of a shot. Fearful of “fake vaccines”…
Last Wednesday, the lower chamber of the Mexican Congress approved a bill that would legalise recreational marijuana. With a population of nearly 130 million people, Mexico would join Canada and…
The latest from Mexico’s fight against COVID-19, including news of vaccine tourism into the US, how China’s CanSino is filling the gaps left by Western companies, and AMLO’s call for…
See our Cookie Privacy Policy Here
